Current Report Filing (8-k)
September 14 2020 - 5:19PM
Edgar (US Regulatory)
0001267813
false
0001267813
2020-09-14
2020-09-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): September 14, 2020
Marinus Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-36576
|
20-0198082
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
5 Radnor Corporate Center, Suite 500
100
Matsonford Rd Radnor,
PA
|
19087
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s telephone number, including area code: (484) 801-4670
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common Stock, par value $0.001
|
MRNS
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On September 14, 2020, Marinus Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing positive data from the Company’s Phase 3 clinical trial
evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder. A copy of the press release
is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
On September 14, 2020, the Company posted
an updated corporate presentation on its website at www.marinuspharma.com. A copy of the presentation is filed herewith as Exhibit
99.2 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MARINUS PHARMACEUTICALS, INC.
|
|
|
|
|
Date: September 14, 2020
|
/s/ Edward Smith
|
|
Edward Smith
|
|
Vice President, Chief Financial Officer, Secretary and Treasurer
|
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024